Corilagin

Corilagin, a gallotannin, has anti-tumor, anti-inflammatory and hepatoprotective activities. Corilagin inhibits activity of reverse transcriptase of RNA tumor viruses. Corilagin also inhibits the growth of Staphylococcus aureus with a MIC of 25 μg/mL. Corilagin shows anti-tumor activity on hepatocellular carcinoma and ovarian cancer model. Corilagin shows low toxicity to normal cells and tissues^[1][2][3]. In Vitro:Corilagin (0-50 μM, 24 h) inhibits SGC7901 and BGC823 cell growth, and the cells became rounded^[2].
Corilagin (0-30 μM, 24 h) induces SGC7901 and BGC823 cell apoptosis^[2].
Corilagin (0-30 μM, 24 h) decreased the protein levels of procaspase-8, -9 and -3 and increases cleaved PARP in SGC7901 and BGC823 cell^[2].
Corilagin (0-30 μM, 24 h) induces autophagy in SGC7901 and BGC823 cell (enhancement of acidic vesicles, increased the level of LC3II)^[2].
Corilagin (0-30 μM, 24 h) induces ROS generation in SGC7901 and BGC823 cell^[2].
Corilagin (40 μM, 24 or 48 h) induces G2 cell cycle arrest and apoptosis in Hey and SKOv3ip cells^[3].
Corilagin (0-80 μM, 1-3 days) inhibits the secretion of TGF-β1 in Hey, SKOv3ip and HO8910PM cells^[3].
In Vivo:Corilagin (15 mg/kg, i.p., for 7 days) shows anti-tumor activity in Hep3B hepatocellular carcinoma^[4].
Corilagin (0-20 mg/kg, i.p.) prevents APAP-induced hepatotoxicity in mice^[5].
Corilagin (10 and 100 mg/kg, i.p.) ameliorates Bleomycin-induced pulmonary fibrosis in mice^[6].